Bucelipase alfa
- Generic Name
- Bucelipase alfa
- Drug Type
- Biotech
- CAS Number
- 9026-00-0
- Unique Ingredient Identifier
- 3C617U1K19
- Background
Bucelipase alfa is under investigation in clinical trial NCT00743483 (Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency).
Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants
- Conditions
- Prevention of Growth Restriction
- Interventions
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 415
- Registration Number
- NCT01413581
- Locations
- 🇸🇪
Swedish Orphan Biovitrum Investigational Site, Umeå, Sweden
Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 15
- Registration Number
- NCT00743483
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇵🇱Specjalistyczny Zespól Opieki Zdrowotnej nad Matka i Dzieckiem w Gdansku, Gdansk, Poland
🇵🇱Uniwersytet Medyczny im. K. Marcinkowskiego, Poznan, Poland
Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Pasteurized Breast Milk for Preterm Infants
- Conditions
- Replacement Therapy in Preterm Infants
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 32
- Registration Number
- NCT00659243
- Locations
- 🇫🇷
Hopital de la Croix Rousse, Lyon, France
🇫🇷Maternité A. Pinard, Néonatologie, Nancy, France
🇫🇷Hopital Saint Vincent de Paul, Paris, France
Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants
- Conditions
- Replacement Therapy in Preterm Infants
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 33
- Registration Number
- NCT00658905
- Locations
- 🇮🇹
Clinical Pediatrica-Neonatologia, Policlinico Gemelli, Universita Cattolica, Rome, Italy
🇮🇹Azienda Ospedaliera "Ospedale Policlinico Consorziale",U.O Neonatologia e Terapia Intensiva Neonatale, Bari, Italy
🇮🇹Presidio Ospedaliero di Alta Specializzazione G.Salesi Azienda Ospedaliero Universitaria Ospedali Riuniti "Umberto I-G.M.Lancisi -G.Salesi, Ancona, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.